Frontotemporal lobar degeneration (FTLD) is a young-onset neurodegenerative condition. The major pathologies causing FTLD include misfolded forms of tau known as FTLD-Tau, TDP-43 proteinopathy known as FTLD-TDP, and other very rare FTLD variants. It is crucial to find features identifying these pathologic forms of FTLD during life to develop reliable diagnostic markers and establish eligibility for disease-modifying therapy trials. Mutations associated with these pathologies are found in 15% of cases. The vast majority of FTLD patients have sporadic disease, but clinical features do not reliably predict FTLD-Tau or FTLD-TDP histopathology, and up to 25% of patients who present with clinical frontotemporal degeneration (FTD) are atypical forms of autopsy-confirmed Alzheimer?s disease (AD). It is thus necessary to collect additional data that reflect the pathologic form of FTLD during life more accurately. This includes clinical, neuropsychological, neuroimaging, genetic markers including single nucleotide polymorphisms (SNPs), and cerebrospinal fluid (CSF) biomarkers. Moreover, disease-modifying treatment trials require well-characterized natural histories of FTLD-related phenotypes to identify markers of a beneficial treatment response. The Clinical Core will work with other cores and projects of this Program Project Grant (PPG) to improve our understanding of disease mechanisms. To this end, we will continue to recruit patients with sporadic clinical FTD who have a high likelihood of having FTLD spectrum pathology, and asymptomatic and symptomatic carriers of mutations associated with FTLD. We will collect multimodal data to help identify the specific form of FTLD pathology to improve diagnostic accuracy in sporadic cases and characterize longitudinal progression, and we will recruit these patients for autopsy. We propose four Specific Aims to achieve these goals.

Public Health Relevance

The Clinical Core will work with other cores and projects of this Program Project Grant (PPG) to improve our understanding of disease mechanisms. To this end, we will continue to recruit patients with sporadic clinical FTD who have a high likelihood of having FTLD spectrum pathology, and asymptomatic and symptomatic carriers of mutations associated with FTLD. We will collect multimodal data to help identify the specific form of FTLD pathology to improve diagnostic accuracy in sporadic cases and characterize longitudinal progression, and we will recruit these patients for autopsy.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG017586-18
Application #
9442655
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2018-03-01
Budget End
2019-02-28
Support Year
18
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Sanchez-Contreras, Monica Y; Kouri, Naomi; Cook, Casey N et al. (2018) Replication of progressive supranuclear palsy genome-wide association study identifies SLCO1A2 and DUSP10 as new susceptibility loci. Mol Neurodegener 13:37
Robinson, John L; Corrada, Maria M; Kovacs, Gabor G et al. (2018) Non-Alzheimer's contributions to dementia and cognitive resilience in The 90+ Study. Acta Neuropathol :
Brettschneider, Johannes; Suh, EunRan; Robinson, John L et al. (2018) Converging Patterns of ?-Synuclein Pathology in Multiple System Atrophy. J Neuropathol Exp Neurol 77:1005-1016
Suh, EunRan; Grando, Kaitlyn; Van Deerlin, Vivianna M (2018) Validation of a Long-Read PCR Assay for Sensitive Detection and Sizing of C9orf72 Hexanucleotide Repeat Expansions. J Mol Diagn 20:871-882
Zee, Jarcy; Xie, Sharon X (2018) The Kaplan-Meier Method for Estimating and Comparing Proportions in a Randomized Controlled Trial with Dropouts. Biostat Epidemiol 2:23-33
Oukoloff, Killian; Kovalevich, Jane; Cornec, Anne-Sophie et al. (2018) Design, synthesis and evaluation of photoactivatable derivatives of microtubule (MT)-active [1,2,4]triazolo[1,5-a]pyrimidines. Bioorg Med Chem Lett 28:2180-2183
Phillips, Jeffrey S; Das, Sandhitsu R; McMillan, Corey T et al. (2018) Tau PET imaging predicts cognition in atypical variants of Alzheimer's disease. Hum Brain Mapp 39:691-708
Smith, Kara M; Ash, Sharon; Xie, Sharon X et al. (2018) Evaluation of Linguistic Markers of Word-Finding Difficulty and Cognition in Parkinson's Disease. J Speech Lang Hear Res 61:1691-1699
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872
Gangishetti, Umesh; Christina Howell, J; Perrin, Richard J et al. (2018) Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease. Alzheimers Res Ther 10:98

Showing the most recent 10 out of 593 publications